• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Chennai, Nov. 21 Spectrum, a division of the Chennai-based biopharmaceutical company ABL Biotechnologies Ltd, is looking at business opportunities offered by the new regulatory environment in the pharmaceutical industry.

At a press conference here on Wednesday, ABL Biotechnologies’ Chairman and Managing Director, Mr K.O. Isaac, said that the full-fledged product development team, regulatory and documentation group, training and strategy team, packaging design group available with it offer it the capability to deliver innovative solutions, problem solving and compliance.

Recent developments such as the re-classification of over 1,258 fixed dose combinations (FDC) by the Drug Controller, restrictions on manufacturing, distribution of these combinations, confusion in the medical community on status of these FDCs, need to get fresh licenses and the time lag involved would all have an adverse impact on the pharmaceutical industry. Losses due to these are estimated at over Rs 3,500 crore, he said.

Spectrum has the expertise to offer solutions for the industry to tackle these issues. The division sees this as a new business opportunity that represents revenues of over Rs 50-100 crore for the company.

Spectrum has introduced novel formulations with over 450 drug licenses at a retail value of over Rs 3,000 crore in the last five years. It has developed and manufactured formulations in a variety of formats including soft gelatine capsules, tablets, capsules, ointments, dry and liquid syrups, injectables and topicals. Some of its neutraceuticals introduced into the market were formulated in India for the first time, Mr Isaac said.

Its customers include Zydus Cadilla, JB Chemicals, Nicholas Piramal, Wallace, Elder and Intas. Spectrum has over 50 formulations under production every month in its nine production facilities for various pharmaceutical companies.

More Stories on : Outlook | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
MM Forgings deploys ERP solution

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line